NCT05980208尚未招募不适用
A Real-world Study of Inetetamab for First-line Treatment of HER2-positive Inoperable Locally Advanced or Relapsed Metastatic Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 150
- 主要终点
- Progression-Free Survival
研究概览
简要总结
This is a prospective, multicenter, real-world study aimed at evaluating the efficacy and safety of inetetamab+chemotherapy or inetetamab+pyrotinib+chemotherapy or inetetamab+pertuzumab+chemotherapy in the treatment of HER2 positive inoperable locally advanced or recurrent metastatic breast cancer. The research results will provide new targeted treatment strategies for HER2 positive breast cancer patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged ≥18 years and ≤75 years;Patients aged ≥18 years and ≤75 years;
- •Her2-positive invasive breast cancer confirmed by pathological examination met the following conditions:
- •Positive HER2 expression: Immunohistochemical staining (IHC) showed positive HER2 3+ and/or fluorescence in situ hybridization (FISH); Tumor staging: inoperable locally advanced or recurrent metastatic breast cancer; Patients with local recurrence must be confirmed by the investigator to be unable to undergo radical surgical excision.
- •At least one measurable lesion was present according to RECIST1.1 criteria;
- •The ECOG score is 0 to 1;
- •No systematic antitumor therapy (except first-line endocrine therapy) has been received at the locally advanced stage (clinically inoperable) or at the stage of recurrence and metastasis;
- •The functional level of major organs must meet the following requirements (no blood transfusion within 2 weeks prior to screening, no use of leukocyte enhancing and platelet enhancing drugs) :
- •Blood routine: neutrophils (ANC) ≥1.5×109/L; Platelet count (PLT) ≥90×109/L; Hemoglobin (Hb) ≥90 g/L;
- •Blood biochemistry: total bilirubin (TBIL) ≤ upper limit of normal value (ULN), known patients with Gilbert syndrome, TBIL≤2×ULN; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5×ULN, patients with liver metastasis required ALT and AST≤5×ULN; Alkaline phosphatase ≤2.5×ULN; Urea/urea nitrogen (BUN) and creatinine (Cr) ≤1.5×ULN;
- •Cardiac ultrasound: left ventricular ejection fraction (LVEF) ≥50%;
- •12-lead electrocardiogram: Fridericia corrected QT interval (QTcF) <470 msec;
- •Expected survival ≥3 months;
- •Participate in this study voluntarily, sign informed consent, have good compliance and be willing to cooperate with follow-up.
排除标准
- •Known allergic history of drug components of the program;
- •Patients judged unsuitable for systematic chemotherapy by researchers;
- •Use of endocrine therapy drugs within 14 days before baseline;
- •Patients with only bone or skin as target lesions;
- •Other malignancies, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or squamous cell carcinoma, within the previous 5 years;
- •Peripheral neuropathy ≥ grade 3 according to CTCAE 5.0 criteria;
- •Had received major surgical procedures or significant trauma within 4 weeks prior to randomization, or was expected to receive major surgical treatment;
- •Serious heart disease or discomfort, including but not limited to:
- •heart failure or contraction dysfunction (LVEF <50%) past medical history high risk or the need for treatment of angina or arrhythmia (such as second degree atrioventricular block type 2 or 3 degree atrioventricular block, ventricular tachycardia) clinical significance of heart valve disease ECG showed wall permeability myocardial infarction poorly controlled hypertension, systolic blood pressure>150 mmHg and/or diastolic blood pressure>100 mmHg
- •Dysphagia, chronic diarrhea, intestinal obstruction and other factors affecting drug delivery and absorption;
- •A history of immunodeficiency, including HIV infection, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation;
- •Participated in other drug clinical studies within 4 weeks prior to screening;
- •There is a third interstitial effusion (such as pleural fluid and ascites) that cannot be controlled by drainage or other methods;
- •Pregnant or lactating women, women of childbearing age who are unable to take effective contraceptive measures throughout the trial period;
- •Have a serious concomitant disease or other co-medical condition that interferes with planned treatment or any other condition that is not suitable for participation in the study, such as active hepatitis B, lung infection requiring treatment, etc.
研究组 & 干预措施
Inetetamab
Inetetamab-based treatment for first-line treatment of HER2-positive MBC
干预措施: Inetetamab (Drug)
结局指标
主要结局
Progression-Free Survival
时间窗: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
The survival time from the date of randomization to the date of the first documented progression or date of death, whichever came first, assessed up to 60 months
次要结局
- Objective Response Rate(From date of randomization until the date at the end of the second treatment cycle (42 days))
- Adverse Events(The time from randomization to reach the endpoint, assessed up to 60 months)
- Overall survival(The time from randomization to death from any cause, whichever came first, assessed up to 60 months)
研究者
相似试验
招募中
1 期
Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung CancerNon-small Cell Lung CancerNCT05016544Sun Yat-sen University48
Unknown
不适用
RWS of Inetetamab HER2 Positive Advanced Breast CancerHER2-positive Advanced Breast CancerNCT04963608Zhiyong Yu100
招募中
不适用
RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old.Acute Myeloid Leukemia, AdultNCT05127798Grupo Argentino de Tratamiento de la Leucemia Aguda50
尚未招募
4 期
Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast CancerBreast CancerNCT05291910Chinese Academy of Medical Sciences70
招募中
不适用
RWE of 1st Line Treatment With ATO/ATRA for Adult APLPromyelocytic Leukemia, Adult AcuteNCT04897490Grupo Argentino de Tratamiento de la Leucemia Aguda50